McKesson Corporation
McKesson Corporation (MCK) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
mck · pe ratio · data through Mar 31, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for McKesson Corporation (MCK) measures how much investors pay for each dollar of the company's trailing earnings. MCK's current PE ratio of 19.89x is calculated by dividing its stock price of $775.66 by its TTM earnings per share of $39.00. −22.5% discount vs 5Y avg 25.6x
Source: FMP · /ratios-ttm · /analyst-estimates · 2026-03-31
PE Ratio History
2007 – 2026 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 19 fiscal years · Front-end computedMinQ1 · 25%19.0x
MedianQ3 · 75%686.1x
Max
At 19.89x, MCK's current P/E is within its average historical range over the past 19 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Distribution · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
McKesson CorporationYou MCK | $93.2B | 19.89x | -25.3% | $39.00 |
 Bristol-Myers Squibb Company BMY | $116.9B | 15.61x | -41.4% | $3.46 |
 Cardinal Health, Inc. CAH | $48.2B | 25.94x | -2.6% | $6.48 |
 Cencora, Inc. COR | $53.5B | 38.98x | +46.4% | $8.02 |
 CVS Health Corporation CVS | $122.4B | 56.87x | +113.6% | $1.40 |
 GSK plc GSK | $103.6B | 6.45x | -75.8% | $5.64 |
 HCA Healthcare, Inc. HCA | $82.6B | 15.88x | -40.4% | $29.40 |
Industry Average 6 peers with valid PE | — | 26.62x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2026-03-31Latest FY2026 | 22.46x | $38.53 | -13.7% | |
2025-03-31 FY2025 | 26.02x | $25.86 | +9.3% | |
2024-03-31 FY2024 | 23.80x | $22.54 | +68.7% | |
2023-03-31 FY2023 | 14.11x | $25.23 | -66.3% | |
2022-03-31 FY2022 | 41.85x | $7.31 | — | |
2021-03-31 FY2021 | — | $-28.26 | — | |
2020-03-31 FY2020 | 27.20x | $4.97 | -96.0% | |
2019-03-31 FY2019 | 686.13x | $0.17 | +56.9% | |
2018-03-31 FY2018 | 437.33x | $0.32 | +6817.9% | |
2017-03-31 FY2017 | 6.32x | $23.45 | -60.5% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for McKesson Corporation (MCK) measures how much investors pay for each dollar of the company's trailing earnings. MCK's current PE ratio of 19.89x is calculated by dividing its stock price of $775.66 by its TTM earnings per share of $39.00.
Frequently asked questions
MCK pe ratio · 6 questionsMCK's current PE ratio is 19.89x as of 2026-06-08, based on a stock price of $775.66 and TTM EPS of $39.00. Data sourced from Financial Modeling Prep via MCK's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · McKesson Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08